These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1279 related articles for article (PubMed ID: 17442104)
1. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). Sader HS; Watters AA; Fritsche TR; Jones RN BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Sader HS; Streit JM; Fritsche TR; Jones RN Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Sader HS; Jones RN Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Sader HS; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2005 Dec; 53(4):329-32. PubMed ID: 16263233 [TBL] [Abstract][Full Text] [Related]
7. [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci]. Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López F; Gómez M; Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):13-6. PubMed ID: 19406529 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Sader HS; Farrell DJ; Jones RN Int J Antimicrob Agents; 2010 Jul; 36(1):28-32. PubMed ID: 20444576 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece. Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Sader HS; Moet GJ; Farrell DJ; Jones RN Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202 [TBL] [Abstract][Full Text] [Related]
12. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers. Sader HS; Watters AA; Fritsche TR; Jones RN J Chemother; 2008 Feb; 20(1):28-32. PubMed ID: 18343740 [TBL] [Abstract][Full Text] [Related]
13. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007). Sader HS; Moet G; Jones RN J Chemother; 2009 Nov; 21(5):500-6. PubMed ID: 19933040 [TBL] [Abstract][Full Text] [Related]
14. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Picazo JJ; Betriu C; Culebras E; Rodríguez-Avial I; Gómez M; López F; Diagn Microbiol Infect Dis; 2009 Aug; 64(4):448-51. PubMed ID: 19631100 [TBL] [Abstract][Full Text] [Related]
15. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections. Wagenlehner FM; Lehn N; Witte W; Naber KG Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498 [TBL] [Abstract][Full Text] [Related]
17. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons. Pfaller MA; Beach ML; Gordon KA; Jones RN J Chemother; 2002 Feb; 14(1):13-8. PubMed ID: 11892893 [TBL] [Abstract][Full Text] [Related]
18. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. Streit JM; Jones RN; Sader HS J Antimicrob Chemother; 2004 Apr; 53(4):669-74. PubMed ID: 14985278 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009). Sader HS; Farrell DJ; Jones RN J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]